



Kansas City

An Independent Licensee of the Blue Cross and Blue Shield Association

Percutaneous Vertebroplasty and Sacroplasty

Policy Number: 6.01.25

Last Review: 11/2018

Origination: 2/2001

Next Review: 11/2019

Policy

Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for percutaneous vertebroplasty when it is determined to be medically necessary because the criteria shown below are met.

When Policy Topic is covered

Percutaneous vertebroplasty may be considered **medically necessary** for the treatment of symptomatic osteoporotic vertebral fractures that have failed to respond to conservative treatment (e.g., analgesics, physical therapy and rest) for at least 6 weeks.

Percutaneous vertebroplasty may be considered **medically necessary** for the treatment of symptomatic osteoporotic vertebral fractures that are less than 6 weeks in duration that have led to hospitalization or persist at a level that prevents ambulation.

Percutaneous vertebroplasty may be considered **medically necessary** for the treatment of severe pain due to osteolytic lesions of the spine related to multiple myeloma or metastatic malignancies.

When Policy Topic is not covered

Percutaneous vertebroplasty is considered **investigational** for all other indications, including use in acute vertebral fractures due to osteoporosis or trauma.

Percutaneous sacroplasty is considered **investigational** for all indications, including use in sacral insufficiency fractures due to osteoporosis and sacral lesions due to metastatic malignancies or multiple myeloma.

Description of Procedure or Service

Populations	Interventions	Comparators	Outcomes
Individuals: • With symptomatic	Interventions of interest are:	Comparators of interest are:	Relevant outcomes include: • Symptoms

osteoporotic vertebral fractures between 6 weeks and 1 year old	<ul style="list-style-type: none"> • Vertebroplasty 	<ul style="list-style-type: none"> • Conservative management 	<ul style="list-style-type: none"> • Functional outcomes • Quality of life • Hospitalizations • Medication use • Treatment-related morbidity
Individuals: <ul style="list-style-type: none"> • With symptomatic osteoporotic vertebral fractures less than 6 weeks old 	Interventions of interest are: <ul style="list-style-type: none"> • Vertebroplasty 	Comparators of interest are: <ul style="list-style-type: none"> • Conservative management 	Relevant outcomes include: <ul style="list-style-type: none"> • Symptoms • Functional outcomes • Quality of life • Hospitalizations • Medication use • Treatment-related morbidity
Individuals: <ul style="list-style-type: none"> • With sacral insufficiency fractures 	Interventions of interest are: <ul style="list-style-type: none"> • Sacroplasty 	Comparators of interest are: <ul style="list-style-type: none"> • Conservative management 	Relevant outcomes include: <ul style="list-style-type: none"> • Symptoms • Functional outcomes • Quality of life • Hospitalizations • Medication use • Treatment-related morbidity

Percutaneous vertebroplasty is an interventional technique involving the fluoroscopically guided injection of polymethylmethacrylate into a weakened vertebral body. The technique has been investigated to provide mechanical support and symptomatic relief in patients with osteoporotic vertebral compression fractures or those with osteolytic lesions of the spine (eg, multiple myeloma, metastatic malignancies); as a treatment for sacral insufficiency fractures; and as a technique to limit blood loss related to surgery.

For individuals who have symptomatic osteoporotic vertebral fractures of between 6 weeks and 1 year old who receive vertebroplasty, the evidence includes 2 randomized sham-controlled trials, nonblinded randomized controlled trials (RCTs) comparing vertebroplasty with conservative management, and systematic reviews of these RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, hospitalizations, medication use, and treatment-related morbidity. Despite the completion of numerous RCTs, including 2 with sham controls, the efficacy of vertebroplasty for painful osteoporotic compression fractures remains uncertain. Two meta-analysis studies which included the 2 sham-controlled trials have demonstrated mixed results. The 2 studies had methodologic issues, including the choice of sham procedure and the potential of the sham procedure to have a therapeutic effect by reducing pain. Questions have also been raised about the low percentage of patients screened who participated in the trial, the volume of polymethylmethacrylate injected, and the inclusion of patients with chronic pain. Overall, conclusions about the effect of vertebroplasty remain unclear. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with symptomatic osteoporotic vertebral fractures less than 6 weeks old who receive vertebroplasty, the evidence includes a randomized sham-

controlled trial and other nonblinded RCTs comparing vertebroplasty with conservative management. Relevant outcomes are symptoms, functional outcomes, quality of life, hospitalizations, medication use, and treatment-related morbidity. For acute fractures, conservative therapy consisting of rest, analgesics, and physical therapy is an option, and symptoms will resolve in a large percentage of patients with conservative treatment only. However, a sham-controlled randomized trial in patients who had severe pain of fewer than 6 weeks in duration found a significant benefit of vertebroplasty for the treatment of osteoporotic vertebral fracture at the thoracolumbar junction. Other RCTs without sham controls have reported that vertebroplasty is associated with significant improvements in pain and reductions in the duration of bedrest. Given the high morbidity associated with extended bedrest in older adults, this procedure is considered to have a significant health benefit. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with sacral insufficiency fractures who receive sacroplasty, the evidence includes 2 prospective cohort studies and a case series. Relevant outcomes are symptoms, functional outcomes, quality of life, hospitalizations, medication use, and treatment-related morbidity. No RCTs have been reported. The available evidence includes a prospective cohort study and a retrospective series of 243 patients. These studies have reported rapid and sustained decreases in pain following percutaneous sacroplasty. Additional literature has mostly reported immediate improvements following the procedure. However, due to the small size of the evidence base, the harms associated with sacroplasty have not been adequately studied. The evidence is insufficient to determine the effects of the technology on health outcomes.

Vertebroplasty has been investigated as an intervention to provide mechanical support and symptomatic relief in patients with an osteoporotic vertebral compression fracture and in those with osteolytic lesions of the spine (ie, multiple myeloma, metastatic malignancies). Clinical input obtained in 2008 provided uniform support for the use of vertebroplasty in painful osteoporotic fractures. Reconsideration of the available evidence and evaluation of the input led to a conclusion that, consistent results of numerous case series, including large prospective reports, the evidence was sufficient to determine that vertebroplasty is a reasonable treatment option in patients with vertebral fractures who have failed to respond to conservative treatment (at least 6 weeks with analgesics, physical therapy, and rest). It is also clinically reasonable to consider the evidence supporting the clinical benefit of vertebroplasty in the osteoporotic vertebral fracture to support its use in osteolytic lesions of the spine (eg, multiple myeloma, metastatic malignancies).

Background

*Note: Percutaneous kyphoplasty is addressed in a separate policy.

OSTEOPOROTIC FRACTURE

Vertebral Compression Fracture

Osteoporotic compression fractures are common. It is estimated that up to one-half of women and approximately one-quarter of men will have a vertebral fracture at some point in their lives. However, only about one-third of vertebral fractures reach clinical diagnosis, and most symptomatic fractures will heal within a few weeks or 1 month. Nonetheless, some individuals with acute fractures will have severe pain and decreased function that interferes with the ability to ambulate and is not responsive to usual medical management. Also, a minority of patients will exhibit chronic pain following osteoporotic compression fracture that presents challenges for medical management.

Treatment

Chronic symptoms do not tend to respond to the management strategies for acute pain such as bedrest, immobilization or bracing device, and analgesic medication, sometimes including narcotic analgesics. The source of chronic pain after vertebral compression fracture may not be from the vertebra itself but may be predominantly related to strain on muscles and ligaments secondary to kyphosis. This type of pain frequently does not improve with analgesics and may be better addressed through exercise. Improvements in pain and ability to function are the principal outcomes of interest for treatment of osteoporotic fractures.

Sacral Insufficiency Fractures

Sacral insufficiency fractures (SIFs) are the consequence of stress on weakened bone and often cause low back pain in the elderly population.¹ Osteoporosis is the most common risk factor for SIF. Spontaneous fracture of the sacrum in patients with osteoporosis was described by Lourie (1982) and presents as lower back and buttock pain with or without referred pain in the legs.² Although common, SIFs can escape detection due to low provider suspicion and poor sensitivity on plain radiographs, slowing the application of appropriate intervention.

Treatment

Similar interventions are used for sacral and vertebral fractures and include bedrest, bracing, and analgesics. Initial clinical improvements may occur quickly; however, resolution of all symptoms may not occur for 9 to 12 months.^{1,3}

Vertebral and Sacral Body Metastasis

Metastatic malignant disease of the spine generally involves the vertebrae/sacrum, with pain being the most frequent complaint.

Treatment

While radiotherapy and chemotherapy are frequently effective in reducing tumor burden and associated symptoms, pain relief may be delayed days to weeks, depending on tumor response. Further, these approaches rely on bone remodeling to regain strength in the vertebrae/sacrum, which may necessitate supportive bracing to minimize the risk of vertebral/sacral collapse during healing.

Improvements in pain and function are the primary outcomes of interest for treatment of bone malignancy with percutaneous vertebroplasty or sacroplasty.

Surgical Treatment Options

Percutaneous Vertebroplasty

Vertebroplasty is a surgical procedure that involves the injection of synthetic cement (eg, polymethylmethacrylate [PMMA], bis-glycidyl dimethacrylate [Cortoss]⁴) into a fractured vertebra. It has been suggested that vertebroplasty may provide an analgesic effect through mechanical stabilization of a fractured or otherwise weakened vertebral body. However, other mechanisms of effect have been postulated, including thermal damage to intraosseous nerve fibers.

Percutaneous Sacroplasty

Sacroplasty evolved from the treatment of insufficiency fractures in the thoracic and lumbar vertebrae with vertebroplasty. The procedure, essentially identical to vertebroplasty, entails guided injection of PMMA through a needle inserted into the fracture zone. While first described in 2000 as a treatment for symptomatic sacral metastatic lesions,^{5,6} it is most often described as a minimally invasive alternative to conservative management⁷⁻⁹ for SIFs.

Pain and function are subjective outcomes and, thus, may be susceptible to placebo effects. Furthermore, the natural history of pain and disability associated with these conditions may vary. Therefore, controlled comparison studies would be valuable to demonstrate the clinical effectiveness of vertebroplasty and sacroplasty over and above any associated nonspecific or placebo effects and to demonstrate the effect of treatment compared with alternatives such as continued medical management.

In all clinical situations, adverse events related to complications from vertebroplasty and sacroplasty are the primary harms to be considered. Principal safety concerns relate to the incidence and consequences of leakage of the injected PMMA or another injectate.⁴

Regulatory Status

Vertebroplasty is a surgical procedure and, as such, is not subject to U.S. Food and Drug Administration (FDA) approval.

PMMA bone cement was available as a drug product before enactment of FDA's device regulation and was at first considered what FDA terms a "transitional device." It was transitioned to a class III device requiring premarketing applications. Several orthopedic companies have received approval of their bone cement products since 1976. In 1999, PMMA was reclassified from class III to class II, which requires future 510(k) submissions to meet "special controls" instead of "general controls" to assure safety and effectiveness. Thus, use of PMMA in vertebroplasty represented an off-label use of an FDA-regulated product before 2005. In 2005, PMMA bone cements such as Spine-Fix® Biomimetic Bone Cement and Osteopal® V were cleared for marketing by FDA through the 510(k)

process for the fixation of pathologic fractures of the vertebral body using vertebroplasty procedures.

The use of PMMA in sacroplasty is an off-label use of an FDA-regulated product (bone cements such as Spine-Fix® Biomimetic Bone Cement [Teknimed] and Osteopal® V [Heraeus]) because the 510(k) approval was for the fixation of pathologic fractures of the vertebral body using vertebroplasty procedures. Sacroplasty was not included. FDA product code: NDN.

In 2009, Cortoss® (Stryker) Bone Augmentation Material was cleared for marketing by FDA through the 510(k) process. Cortoss® is a nonresorbable synthetic material that is a composite resin-based, bis-glycidal dimethacrylate. FDA classifies this product as a PMMA bone cement.

In 2010, the Parallax® Contour® Vertebral Augmentation Device (ArthroCare) was cleared for marketing by FDA through the 510(k) process. The device creates a void in cancellous bone that can then be filled with bone cement. FDA product code: HXG.

Rationale

This evidence review was created in April 2000 and has been updated regularly with searches of the MEDLINE database. The most recent literature update was performed through February 22, 2018.

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Percutaneous Vertebroplasty For Vertebral Compression Fractures of between 6 weeks and 1 Year old

This evidence review was informed by a TEC Assessment (2000), which was updated periodically through 2010.¹⁰⁻¹⁵ Subsequent evidence includes a number of RCTs, two of which included a sham control, and numerous RCTs that compared vertebroplasty with conservative management.

Systematic Reviews

A Cochrane review by Buchbinder et al (2015) evaluated the evidence on vertebroplasty for the treatment of vertebral compression fractures.¹⁶ Eleven RCTs and a quasi-RCT were included. Two trials identified compared vertebroplasty with a sham procedure (n=209 patients; Buchbinder et al [2009]¹⁷ and Kallmes et al [2009],¹⁸ detailed below), six compared vertebroplasty with usual care (n=566), and four compared vertebroplasty with kyphoplasty (n=545). The sham-controlled trials were considered to be at low risk of bias. All other trials were judged at high risk of bias due to lack of blinding. Evidence was rated as moderate quality based on the low number of subjects in the sham-controlled trials. Meta-analysis of the 2 sham-controlled trials indicated that vertebroplasty did not result in clinically significant improvements in pain, disability, quality of life, or treatment success. Results did not differ for patients who had pain durations of 6 weeks or less compared with pain lasting more than 6 weeks. Sensitivity analysis indicated that studies comparing vertebroplasty with conservative management were likely to have overestimated the treatment effect. The rate of serious adverse events did not differ significantly between the vertebroplasty and control groups, but serious adverse events related specifically to the vertebroplasty procedure included osteomyelitis, cord compression, thecal sac injury, and respiratory failure.

Staples et al (2011) conducted a patient-level meta-analysis of the 2 sham-controlled trials (described below) to determine whether vertebroplasty is more effective than sham in specific subsets of patients.¹⁹ This subset analysis focused on duration of pain (≤ 6 weeks vs > 6 weeks) and severity of pain (score < 8 or ≥ 8 on an 11-point numeric rating scale [NRS]). Included in the analysis were 209 participants (78 from the Australian trial, 131 from the U.S. trial); 27% had pain of recent onset, and 47% had severe pain at baseline. The primary outcome measures (pain scores and function on the Roland-Morris Disability Questionnaire [RMDQ] at 1 month) did not differ significantly between groups. Responder analyses were also conducted based on a 3-unit improvement in pain scores, a 3-unit improvement in RMDQ scores, and a 30% improvement in each of the pain and disability outcomes. The only difference observed between groups was a trend for a higher proportion of the vertebroplasty group to achieve at least 30% improvement in pain scores (relative risk, 1.32; 95% confidence interval [CI], 0.98 to 1.76; $p=0.07$), a result that may have been confounded by the greater use of opioid medications in that group.

Xie et al (2017), in a meta-analysis of RCTs, evaluated efficacy and safety in percutaneous vertebroplasty and conservative treatment for patients with osteoporotic vertebral compression fractures.²⁰ Thirteen studies were selected (total N=1231 patients; 623 to vertebroplasty, 608 to conservative treatment);

among them were the two sham-controlled trials described below. Outcomes included pain relief (from 1 week to 6 months), quality of life assessments, and the rate of adjacent-level vertebral fracture. Vertebroplasty was superior for pain relief at 1 week (mean difference [MD], 1.36; 95% CI, 0.55 to 2.17) and 1 month (MD=1.56; 95% CI, 0.43 to 2.70); it was inferior to conservative treatment for pain relief at 6 months (MD = -1.59; 95% CI, -2.9 to -0.27; $p < 0.05$). Vertebroplasty showed improvement over conservative treatment for quality of life, as measured using the Quality of Life Questionnaire of the European Foundation for Osteoporosis (MD = -5.03; 95% CI, 7.94 to -2.12). No statistically significant differences were found between treatments for the rate of adjacent-level vertebral fractures (relative risk: 0.59; 95% CI, 0.43 to 0.81). Limitations included the inclusion of several studies with inadequate blinding and heterogenous reporting of patient characteristics outcomes.

Randomized Controlled Trials

Vertebroplasty vs Medical Management With Sham Controls

Two sham-controlled trials published in 2009 were included in the systematic reviews described above. The 2 RCTs compared vertebroplasty with medical management using a sham control (that included local anesthetic), which mimicked the vertebroplasty procedure up to the point of cement injection.^{17,18} Buchbinder et al reported on results for a 4-center, randomized, double-blind, sham-controlled trial with 78 patients with 1 or 2 painful osteoporotic vertebral fractures with a duration of less than 1 year.¹⁷ Patients were assigned to vertebroplasty or sham procedure (ie, injection of local anesthetic into the facet capsule and/or periosteum). Ninety-one percent of participants completed 6 months of follow-up. The participants, investigators (other than the radiologists performing the procedure), and outcome assessors were blinded to the treatment assignment. Blinding was maintained through 24-month follow-up of this trial.²¹

The primary outcome was overall pain (over the course of the previous week) measured on a visual analog scale (VAS) from 0 to 10, with 1.5 points representing the minimal clinically important difference. A sample size of 24 per group was calculated to provide sufficient power to show a 2.5-point postprocedure difference assuming a 3-point standard deviation. All analyses were performed using intention-to-treat (ITT) principles. For the primary outcome, reviewers reported no significant differences in VAS pain score at 3, 12, or 24 months. With reductions in pain and improvements in quality of life observed in both groups, the authors concluded vertebroplasty provided no benefit.

Kallmes et al (2009) conducted a multicenter, randomized, double-blind, sham-controlled trial (INVEST) in which 131 participants with 1 to 3 painful osteoporotic vertebral fractures were assigned to vertebroplasty or sham procedure (injection of local anesthetic into the facet capsule and/or periosteum).¹⁸ Participants had back pain for no more than 12 months and had a current pain rating of at least 3 on VAS at baseline. Participants were evaluated at baseline, and at various time points to 1 year postprocedure. Ninety-seven percent completed a 1-month follow-up, and 95% completed 3 months. The primary outcomes were RMDQ scores and

average back pain intensity during the preceding 24 hours at 1 month, with a reduction of 30% in RMDQ and VAS pain scores considered a clinically meaningful difference.²² The trial initially had 80% power to detect differences in both primary and secondary outcomes with 250 patients, with a 2.5-unit advantage for vertebroplasty over placebo on the RMDQ and 1.0-point difference on the VAS. After recruitment difficulty and interim analysis on the first 90 participants, the target sample size was decreased to 130 participants with 80% power for primary aims maintained. All primary analyses were performed using ITT principles and results presented as mean scores for the RMDQ and pain intensity.

For the primary end points at 1 month, there were no significant between-group differences. There was a trend toward a higher clinically meaningful improvement in pain at 1 month (30% reduction from baseline) in the vertebroplasty group (64% vs 48%, respectively; $p=0.06$). At 3 months, 51% from the control group and 13% in the vertebroplasty group crossed over ($p<0.001$). The crossovers did not affect trial outcomes because they occurred after the primary outcome assessment. By 1 year, 16% of patients who underwent vertebroplasty and 60% of control subjects had crossed over to the alternative procedure ($p<0.001$).²³ The as-treated analysis found no significant difference in RMDQ or pain scores between the 2 groups. ITT analysis found a modest 1-point difference in pain rating and no significant difference in RMDQ score. There was a significant difference in the percentage of patients showing a 30% or greater improvement in pain (70% of patients randomized to vertebroplasty vs 45% of patients randomized to the control group).

Vertebroplasty vs Medical Management Without Sham Controls

Chen et al (2014) reported on a nonblinded RCT comparing vertebroplasty with conservative management.²⁴ The trial included 89 patients with chronic compression fractures confirmed by magnetic resonance imaging and persistent severe pain for 3 months or longer. The evaluation was performed at 1 week and 1, 3, 6, and 12 months. Over the course of 1 year, pain scores decreased from 6.5 to 2.5 in the vertebroplasty group and from 6.4 to 4.1 in the control group ($p<0.001$). Complete pain relief was reported by 84.8% of patients in the vertebroplasty group and 34.9% of controls. The final Oswestry Disability Index (ODI) score was 15.0 in the vertebroplasty group and 32.1 in the conservative management group ($p<0.001$), and the final RMDQ score was 8.1 for vertebroplasty and 10.7 for controls ($p<0.001$).

Farrokhi et al (2011) reported on a blinded RCT that compared vertebroplasty with optimal medical management in 82 patients.²⁵ Patients had painful osteoporotic vertebral compression fractures that were refractory to analgesic therapy for at least 4 weeks and less than 1 year. The patients and the physicians involved in the treatment group were not aware of the treatment the other group was receiving. Control of pain and improvement in quality of life were measured by independent raters before treatment and at 1 week and 2, 6, 12, 24, and 36 months after treatment began. Radiologic evaluation to measure vertebral body height and correction of deformity was performed before and after treatment and after 36 months of follow-up. At 1 week, the mean VAS score decreased from 8.4 to 3.3 in

the vertebroplasty group and from 7.2 to 6.4 in the conservative management group, with between-group differences that remained statistically significant through 6 months of follow-up. Group differences on the ODI lower back pain score were significantly lower in the vertebroplasty group throughout the 36 months of the study. New symptomatic adjacent fractures developed in 1 (2.6%) patient in the vertebroplasty group and 6 (15.4%) patients in the conservative management group. In 1 patient, epidural cement leakage caused severe lower-extremity pain and weakness that was treated with bilateral laminectomy and evacuation of bone cement.

Nonrandomized Comparative Studies

Edidin et al (2011, 2015) reported on mortality risk rates in Medicare patients who had vertebral compression fractures and were treated with vertebroplasty, kyphoplasty, or nonoperatively.^{26,27} These studies were industry-funded. In the 2015 report, they identified 1,038,956 patients who had vertebral compression fractures between 2005 and 2009. The dataset included 141,343 kyphoplasty patients and 75,364 vertebroplasty patients. Survival was calculated from the index diagnosis date until death or the end of follow-up (up to 4 years). Propensity matching was used to control for multiple covariates, which included age, sex, race, census region, socioeconomic status, comorbidities in 12 months before diagnosis, type of fracture, and year of fracture. The matched cohort included 100,649 nonoperated patients, 36,657 kyphoplasty patients, and 24,313 vertebroplasty patients. Analysis of the whole data set before matching indicated that patients in the nonoperated cohort had a 55% (95% CI, 53% to 56%, $p < 0.001$) higher risk of mortality than the kyphoplasty cohort and a 25% (95% CI, 23% to 26%, $p < 0.001$) higher mortality risk than the vertebroplasty cohort. After propensity matching, the risk of mortality at 4 years was 47.2% in the nonoperated group compared with 42.3% in the kyphoplasty group ($p < 0.001$) and 46.2% in the vertebroplasty group ($p < 0.001$).

Lin et al (2017) reported on mortality risk in elderly patients (>70 years old) who had vertebral compression fractures and were treated with early vertebroplasty (within 3 months) or conservative therapy.²⁸ The data set consisted of 10,785 Taiwanese patients who were selected through the National Health Insurance Research Database, of whom 1773 patients received vertebroplasty, and 5324 did not; a minority of these patients had osteoarthritis. Using conditional Cox proportional hazard modeling to determine the risk of death and respiratory-related issues, the authors found that a "significant difference in survival curves of mortality and respiratory failure" existed between both groups of patients ($p < 0.05$). The incidence of death at 1 year in the vertebroplasty group was 0.46 per 100 person-months (95% CI, 0.38 to 0.56). The incidence of death at 1 year in the nonvertebroplasty group was 0.63 per 100 person-months (95% CI, 0.57 to 0.70). With regard to respiratory failure, hazard ratio between groups was 1.46 (95% CI, 1.04 to 2.05; $p = 0.028$). Limitations of this study included the broad selection of the population, which was not restricted only to patients with osteoporotic lesions. Also, authors were limited by the database, which did not report on pain or functional outcomes.

Section Summary: Percutaneous Vertebroplasty for Vertebral Compression Fractures of Between 6 Weeks and 1 Year Old

Despite evidence from numerous RCTs, including two with sham controls, the efficacy of vertebroplasty for painful osteoporotic compression fractures of less than 1 year remains uncertain. Two meta-analysis studies are present, both of which include the 2 randomized, sham-controlled trials from 2009, but have mixed results. There remains some uncertainty related to the interpretation of these conclusions. While the use of a sham procedure is a major methodologic strength to control for nonspecific (placebo) effects, the sham used is controversial, given that the effect of injecting local anesthetic in the facet capsule and/or periosteum is unknown. Also, the appropriateness of outcome measures used to detect clinically meaningful differences in pain might not have been optimal, because the studies were underpowered to detect differences in clinical response rates. Questions have also been raised about the low percentage of patients screened who participated in the trial, the volume of polymethylmethacrylate (PMMA) injected, and the inclusion of patients with chronic pain.

Percutaneous Vertebroplasty For Vertebral Compression Fractures of less Than 6 Weeks old

Randomized Controlled Trials

Vertebroplasty vs Medical Management With Sham Controls

Clark et al (2016) reported on results from the VAPOUR trial (see Table 1).²⁹ VAPOUR was a multicenter, double-blind trial of vertebroplasty in 120 patients with vertebral fractures of less than 6 weeks in duration and back pain of at least 7 out of 10 on an NRS. This trial followed a similar protocol as that used in the Kallmes trial (discussed above). Outcomes assessors and patients were masked to treatment allocation, and independent statisticians unmasked the data and prepared the trial report. The sham-vertebroplasty procedure included subcutaneous lidocaine but no periosteal numbing. Manual skin pressure and tapping on the needle was performed to simulate the needle advance, and the investigators discussed PMMA mixing and injection during the procedure. The primary outcome (the percentage of patients with an NRS score <4 out of 10 at 14 days postprocedure) was met in a greater percentage of patients in the vertebroplasty group (44%) than in the sham control group (21%). This between-group difference was maintained through 6 months.

Table 1. Results From the Sham-Controlled Trial of Vertebroplasty

Outcomes	Vertebroplasty		Sham		Difference (95% CI)	p
	n	n (%) or Mean (SD)	n	n (%) or Mean (SD)		
Proportion of patients with NRS score <4 ^a						
14 days	55	24 (44%)	57	12 (21%)	23 (6 to 39)	0.011
6 months	51	35 (69%)	51	24 (47%)	22 (3 to 40)	0.027
Reduction in NRS pain score						

14 days	55	4.2 (2.7)	57	3.0 (3.0)	1.2 (0.1 to 2.3)	0.026
6 months	51	6.1 (3.3)	51	4.8 (3.1)	1.3 (0 to 2.6)	0.043
Reduction in RMDQ scores						
14 days	53	5.9 (5.8)	56	4.1 (6.3)	1.8 (-0.5 to 4.1)	0.121
6 months	49	11.7 (6.5)	51	7.4 (6.9)	4.2 (1.6 to 6.9)	0.002
VAS pain score (patient-reported)						
14 days	41	39 (28)	47	49 (28)	10 (-2 to 22)	0.096
6 months	42	23 (26)	46	34 (27)	11 (0 to 23)	0.050
VAS pain score (physician-observed)						
14 days	41	25 (23)	48	39 (29)	14 (3 to 26)	0.015
6 months	39	14 (21)	46	19 (20)	5 (-4 to 13)	0.301
QUALEFFO score						
14 days	48	49 (13)	54	55 (14)	6 (1 to 11)	0.029
6 months	46	38 (15)	48	45 (16)	7 (1 to 13)	0.032
EQ-5D score						
14 days	49	0.69 (0.10)	56	0.68 (0.11)	-0.01 (-0.06 to 0.03)	0.471
6 months	47	0.80 (0.11)	50	0.74 (0.12)	-0.06 (-0.10 to -0.01)	0.012
Analgesic use ^b						
14 days	56	49 (88%)	57	52 (91%)	4 (-8 to -15)	0.520
6 months	50	29 (58%)	51	39 (76%)	18 (1 to 36)	0.048

Adapted from Clark et al (2016).²⁹

CI: confidence interval; EQ-5D; EuroQoL 5 dimensions questionnaire; NRS: Numeric rating scale pain; RMDQ: Roland-Morris Disability Questionnaire; QUALEFFO: Quality of life questionnaire of the European Foundation for Osteoporosis; VAS: visual analog scale.

^a Primary end point.

^b Proportion of patients using analgesic medication within the previous 24 hours.

Other outcome measures were significantly improved in the vertebroplasty group at one or both of the time points (see Table 1). The benefit of vertebroplasty was found predominantly in the thoracolumbar subgroup, with 48% (95% CI, 27% to 68%) more patients meeting the primary end point (61% in the vertebroplasty group vs 13% in the control group). The investigators commented that the thoracolumbar junction is subject to increased dynamic load, and fractures at this junction have the highest incidence of mobility. No benefit from vertebroplasty was found in the nonthoracolumbar subgroup. Postprocedural hospital stay was reduced from a mean of 14 days in the control group to 8.5 days after vertebroplasty, even though physicians who determined the discharge date remained blinded to treatment. In the vertebroplasty group, there were 2 serious adverse events due to sedation and transfer to the radiology table. In the control group, 2 patients developed spinal cord compression; one underwent decompressive surgery and the other, not a surgical candidate, became paraplegic.

Vertebroplasty vs Medical Management Without Sham Controls

Klazen et al (2010) reported on VERTOS II, an open-label randomized trial of 202 patients at 6 hospitals in the Netherlands and Belgium.³⁰ Of 431 patients eligible for randomization, 229 (53%) had spontaneous pain relief during assessment.

Participants with at least 1 painful osteoporotic vertebral fracture of 6 weeks or less in duration were assigned to vertebroplasty or conservative management (ie, bedrest, analgesia, cast, physical support). The primary outcome was pain relief of 3 points measured on a 10-point VAS at 1 month and 1 year. A sample size of 100 per group was calculated to provide sufficient power to show a 25% difference in pain relief. All analyses were performed using ITT principles. Clinically significant pain relief was defined as a 30% change in VAS score (0-10 scale).

One hundred one subjects were enrolled in the treatment group and the control arm; 81% completed 12-month follow-up. There were no significant differences in the primary outcome (pain relief of 3 points) measured at 1 month and 1 year. Vertebroplasty resulted in greater pain relief than did medical management through 12 months (<0.001); there were significant between-group differences in mean VAS scores at 1 month (2.6; 1.74 to 3.37; $p<0.001$) or at 1 year (2.0; 1.13 to 2.80; $p<0.001$). Survival analysis showed significant pain relief was quicker (29.7 days vs 115.6 days) and was achieved by more patients after vertebroplasty than after conservative management.

Yi et al (2014) assessed the occurrence of new vertebral compression fractures after treatment with cement augmenting procedures (vertebroplasty or kyphoplasty) vs conservative treatment in an RCT with 290 patients (363 affected vertebrae).³¹ Surgically treated patients were discharged the next day. Patients treated conservatively (pain medication, bedrest, body brace, physical therapy) had a mean length of stay of 13.7 days. Return to usual activity occurred at 1 week for 87.6% of operatively treated patients and 2 months for 59.2% of conservatively treated patients. All patients were evaluated with radiographs and magnetic resonance imaging at 6 months and then at yearly intervals until the last follow-up session. At a mean follow-up of 49.4 months (range, 36-80 months), 10.7% of patients had experienced 42 new symptomatic vertebral compression fractures. There was no significant difference in the incidence of new vertebral fractures between the operative (18 total; 9 adjacent, 9 nonadjacent) and conservative (24 total; 5 adjacent, 16 nonadjacent, 3 same level) groups, but the mean time to a new fracture was significantly shorter in the operative group (9.7 months) than in the nonoperative group (22.4 months).

Leali et al (2016) published a brief report on a multicenter RCT enrolling 400 patients with osteoporotic thoracic or lumbar vertebral compression fractures who were treated with vertebroplasty or conservative therapy.³² Fractures were treated within 2 weeks of pain onset. Details of randomization and rates of follow-up were not reported. At 1 day after treatment, the vertebroplasty group had a reduction in pain scores and improvement in physical function, with VAS pain scores decreasing from 4.8 (maximum, 5.0) to 2.3 ($p=0.023$) and ODI scores improving from 53.6% to 31.7% ($p=0.012$). Sixty-five percent of patients treated with vertebroplasty had stopped all analgesic use within 48 hours. The conservatively managed group showed no benefit in the first 48 hours, but by 6 weeks VAS and ODI scores were described as similar in both groups (specific data not reported). Evaluation of this trial was limited by incomplete reporting.

Yang et al (2016) compared vertebroplasty with conservative therapy in 135 patients over 70 years of age with severe back pain due to an osteoporotic vertebral fracture after minor or mild trauma.³³ Vertebroplasty was performed at a mean of 8.4 days after pain onset. Patients in the conservative therapy group were placed on bedrest and analgesics for at least 2 weeks after diagnosis, followed by bracing and assistive devices. All patients receiving vertebroplasty could stand and walk with a brace at 1 day, posttreatment while only 12 (23.5%) patients could stand up and walk after 2 weeks of bedrest. The average duration of bedrest from pain onset was 7.8 days (range, 2-15 days) in the vertebroplasty group compared with 32.5 days (range, 14-60 days) in the conservative therapy group. At 1-year follow-up, there was a similar percentage of additional compression fractures, but a significantly higher complication rate in the conservative therapy group (35.3%) than in the vertebroplasty group (16.1%; $p < 0.001$). Complications included pneumonia, urinary tract infection, deep vein thrombosis, depression, and sleep disorders.

Section Summary: Percutaneous Vertebroplasty for Vertebral Compression Fractures of Less Than 6 Weeks Old

In a sham-controlled randomized trial, where no anesthetic was injected into the periosteum, there was a significant benefit of vertebroplasty in patients who had severe pain of fewer than 6 weeks in duration following vertebral fracture at the thoracolumbar junction. Other RCTs without sham controls have reported that vertebroplasty is associated with significant improvements in pain, earlier improvements in function, and reductions in the duration of bedrest compared with conservatively managed patients.

Percutaneous Sacroplasty

Sacroplasty is an evolving technique achieved using numerous methods (short-axis, long-axis, balloon-assisted short-axis, iliosacral screws). No randomized trials of sacroplasty were identified. The largest prospective report is an observational cohort study by Frey et al (2008) who assessed 52 consecutive patients undergoing sacroplasty for sacral insufficiency fractures using the short-axis technique.³⁴ Patients had a mean age of 75.9 years, mean duration of symptoms of 34.5 days (range, 4-89 days), and mean VAS score of 8.1 at baseline. Improvements in VAS scores were measured at 30 minutes and 2, 4, 12, 24, and 52 weeks postprocedure. At each interval, statistically significant improvements over baseline were observed and maintained through 52 weeks.

The largest series identified is a retrospective multicenter analysis by Kortman et al (2013) who evaluated 204 patients with painful sacral insufficiency fractures and 39 patients with symptomatic sacral lesions treated with the short-axis or long-axis technique.³⁵ One hundred sixty-nine patients had bilateral sacral insufficiency fractures, and 65 patients had additional fractures of the axial skeleton. VAS scores improved from 9.2 before treatment to 1.9 after treatment in patients with sacral insufficiency fractures, and from 9.0 to 2.6 in patients with sacral lesions. There was 1 case of radicular pain due to extravasation of cement requiring surgical decompression.

Frey et al (2017) reported on patients treated with percutaneous sacroplasty, particularly the long-term efficacy of sacroplasty vs nonsurgical management.³⁶ This prospective, observational cohort study spanned ten years and comprised 240 patients with sacral insufficiency fractures. Thirty-four patients were treated with nonsurgical methods, and 210 patients were treated with sacroplasty. Pain, as measured by VAS, was recorded before treatment and at several follow-ups. Mean pretreatment VAS for the sacroplasty group was 8.29; for the nonsurgical treatment group, it was 7.47. Both forms of treatment resulted in significant VAS improvement from pretreatment to the 2-year follow-up ($p < 0.001$). However, the sacroplasty treatment group experienced significant VAS score improvement consistently at many of the follow-up points (pretreatment to post [$p < 0.001$]; posttreatment through 2 weeks [$p > 0.001$]; 12 weeks through 24 weeks [$p = 0.014$]; 24 weeks through 1 year [$p = 0.002$]). Meanwhile, the group with nonsurgical treatment only experienced one significant pain improvement score—at the 2-week follow-up posttreatment ($p = 0.002$). One major limitation of this study was that the nonsurgical treatment group was not followed up with at the 10-year mark whereas the sacroplasty group did receive follow-up.

There are several retrospective reviews with about 50 patients each. One reported by Dougherty et al (2014) described a series of 57 patients treated with sacroplasty for sacral insufficiency fractures.³⁷ The short- or the long-axis approach was dictated by the length and type of the fracture and patient anatomy. Follow-up data at 2.5 weeks were available for 45 (79%) patients, and the outcome measures were inconsistent. For example, activity pain scores were collected from 13 patients, and rest pain scores were collected from 29 patients. Of the 45 patients with outcomes data, 37 (82%) had experienced a numeric or descriptive decrease from initial pain of at least 30%.

Adverse Events

There are complications related to cement leakage with sacroplasty that are not observed with vertebroplasty. Leakage of PMMA into the presacral space, spinal canal, sacral foramen, or sacroiliac joint may result in pelvic injection of PMMA, sacral nerve root or sacral spinal canal compromise, or sacroiliac joint dysfunction.³⁸ Performing sacroplasty only on zone 1 fractures can minimize these risks.³⁹

Section Summary: Percutaneous Sacroplasty

No RCTs evaluating percutaneous sacroplasty for sacral insufficiency were identified. The available evidence includes two prospective cohort studies and a retrospective series. These studies have reported rapid and sustained decreases in pain following percutaneous sacroplasty. Additional reports are mostly consistent in reporting immediate improvement following the procedure. Due to the small sample size of the evidence base, harms associated with sacroplasty have not been adequately studied. The small numbers of treated patients leave uncertainty regarding the impact of sacroplasty on health outcomes.

Summary of Evidence

For individuals who have symptomatic osteoporotic vertebral fractures of between 6 weeks and 1 year old who receive vertebroplasty, the evidence includes 2 randomized sham-controlled trials, nonblinded RCTs comparing vertebroplasty with conservative management, and systematic reviews of these RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, hospitalizations, medication use, and treatment-related morbidity. Despite the completion of numerous RCTs, including 2 with sham controls, the efficacy of vertebroplasty for painful osteoporotic compression fractures remains uncertain. Two meta-analysis studies which included the 2 sham-controlled trials have demonstrated mixed results. The 2 studies had methodologic issues, including the choice of sham procedure and the potential of the sham procedure to have a therapeutic effect by reducing pain. Questions have also been raised about the low percentage of patients screened who participated in the trial, the volume of polymethylmethacrylate injected, and the inclusion of patients with chronic pain. Overall, conclusions about the effect of vertebroplasty remain unclear. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with symptomatic osteoporotic vertebral fractures less than 6 weeks old who receive vertebroplasty, the evidence includes a randomized sham-controlled trial and other nonblinded RCTs comparing vertebroplasty with conservative management. Relevant outcomes are symptoms, functional outcomes, quality of life, hospitalizations, medication use, and treatment-related morbidity. For acute fractures, conservative therapy consisting of rest, analgesics, and physical therapy is an option, and symptoms will resolve in a large percentage of patients with conservative treatment only. However, a sham-controlled randomized trial in patients who had severe pain of fewer than 6 weeks in duration found a significant benefit of vertebroplasty for the treatment of osteoporotic vertebral fracture at the thoracolumbar junction. Other RCTs without sham controls have reported that vertebroplasty is associated with significant improvements in pain and reductions in the duration of bedrest. Given the high morbidity associated with extended bedrest in older adults, this procedure is considered to have a significant health benefit. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals with sacral insufficiency fractures who receive sacroplasty, the evidence includes 2 prospective cohort studies and a case series. Relevant outcomes are symptoms, functional outcomes, quality of life, hospitalizations, medication use, and treatment-related morbidity. No RCTs have been reported. The available evidence includes a prospective cohort study and a retrospective series of 243 patients. These studies have reported rapid and sustained decreases in pain following percutaneous sacroplasty. Additional literature has mostly reported immediate improvements following the procedure. However, due to the small size of the evidence base, the harms associated with sacroplasty have not been adequately studied. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2014 Input

In response to requests, input was received from 2 physician specialty societies and 3 academic medical centers while this policy was under review in 2014. Input was sought on the treatment of acute vertebral fractures when there is severe pain that has led to hospitalization or persists at a level that prevents ambulation, and on the treatment of traumatic fractures that have remained symptomatic after 6 weeks of conservative treatment. Input on these issues was mixed.

2008 Input

In response to requests, input was received from 5 physician specialty societies and 2 academic medical centers while this policy was under review in 2008. Unsolicited input was received from a sixth physician specialty society. All reviewers disagreed with the proposed policy and provided references in support of the use of vertebroplasty.

Practice Guidelines and Position Statements

American College of Radiology et al

The American College of Radiology and 4 other medical specialty associations updated a 2012 joint position statement on percutaneous vertebral augmentation in 2014.⁴⁰ The statement indicated that percutaneous vertebral augmentation with the use of vertebroplasty or kyphoplasty is a safe, efficacious, and durable procedure in appropriate patients with symptomatic osteoporotic and neoplastic fractures, when performed in accordance with public standards. The document also stated that these procedures are offered only when nonoperative medical therapy has not provided adequate pain relief, or pain is significantly altering patients' quality of life.

Society for Interventional Radiology

In a 2014 quality improvement guideline from the Society for Interventional Radiology, failure of medical therapy was defined as follows⁴¹:

1. "For a patient rendered nonambulatory as a result of pain from a weakened or fractured vertebral body, pain persisting at a level that prevents ambulation despite 24 hours of analgesic therapy;
2. For a patient with sufficient pain from a weakened or fractured vertebral body that physical therapy is intolerable, pain persisting at that level despite 24 hours of analgesic therapy; or

3. For any patient with a weakened or fractured vertebral body, unacceptable side effects such as excessive sedation, confusion, or constipation as a result of the analgesic therapy necessary to reduce pain to a tolerable level.”

American Academy of Orthopaedic Surgeons

The American Academy of Orthopaedic Surgeons (AAOS) approved practice guidelines (2010) on the treatment of osteoporotic spinal compression fractures.⁴² AAOS approved a strong recommendation against the use of vertebroplasty for patients who “present with an osteoporotic spinal compression fracture on imaging with correlating clinical signs and symptoms and who are neurologically intact.” With this recommendation, AAOS expressed its confidence that future evidence is unlikely to overturn the existing evidence. These recommendations were based on a literature review through September 2009; therefore, the 2010 Klazen trial was not considered.

National Institute for Health and Care Excellence

The National Institute for Health and Care Excellence (NICE) concluded in its 2003 guidance on percutaneous vertebroplasty that the current evidence on the safety and efficacy of vertebroplasty for vertebral compression fractures appeared “adequate to support the use of this procedure” to “provide pain relief for people with severe painful osteoporosis with loss of height and/or compression fractures of the vertebral body....”⁴³ The guidance also recommended that the procedure be limited to patients whose pain is refractory to more conservative treatment. A 2013 NICE guidance indicated that percutaneous vertebroplasty and percutaneous balloon kyphoplasty “are recommended as options for treating osteoporotic vertebral compression fractures” in persons having “severe, ongoing pain after a recent, unhealed vertebral fracture despite optimal pain management” and whose “pain has been confirmed to be at the level of the fracture by physical examination and imaging.”⁴⁴

In 2008, NICE issued guidance on the diagnosis and management of adults with metastatic spinal cord compression.⁴⁵ This guidance indicated that vertebroplasty or kyphoplasty should be considered for “patients who have vertebral metastases and no evidence of MSCC [metastatic spinal cord compression] or spinal instability if they have: mechanical pain resistant to conventional pain management, or vertebral body collapse.”

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 2.

Table 2. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT02370628	Vertebroplasty in the treatment of acute fracture trial (The VITTA Trial)	495	Apr 2018
NCT02902250	The Comparative Study About the Effect of Vertebral Body Decompression Procedure and Conservative Treatment for Benign Vertebral Compression Fracture - Prospective Randomized Control Study	80	Apr 2018
NCT02489825	Pilot Study: Does Preventive Adjacent Level Cement Augmentation Positively Affect Reoperation Rates After Osteoporotic Vertebral Compression Fractures?	100	Dec 2018

NCT: national clinical trial.

References

1. Gotis-Graham I, McGuigan L, Diamond T, et al. Sacral insufficiency fractures in the elderly. *J Bone Joint Surg Br.* Nov 1994;76(6):882-886. PMID 7983111
2. Lourie H. Spontaneous osteoporotic fracture of the sacrum. An unrecognized syndrome of the elderly. *JAMA.* Aug 13 1982;248(6):715-717. PMID 7097924
3. Lin J, Lachmann E, Nagler W. Sacral insufficiency fractures: a report of two cases and a review of the literature. *J Womens Health Gend Based Med.* Sep 2001;10(7):699-705. PMID 11571100
4. Bae H, Hatten HP, Jr., Linovitz R, et al. A prospective randomized FDA-IDE trial comparing Cortoss with PMMA for vertebroplasty: a comparative effectiveness research study with 24-month follow-up. *Spine (Phila Pa 1976).* Apr 1 2012;37(7):544-550. PMID 21738093
5. Dehdashti AR, Martin JB, Jean B, et al. PMMA cementoplasty in symptomatic metastatic lesions of the S1 vertebral body. *Cardiovasc Intervent Radiol.* May-Jun 2000;23(3):235-237. PMID 10821903
6. Marcy PY, Palussiere J, Descamps B, et al. Percutaneous cementoplasty for pelvic bone metastasis. *Support Care Cancer.* Nov 2000;8(6):500-503. PMID 11094996
7. Aretxabala I, Fraiz E, Perez-Ruiz F, et al. Sacral insufficiency fractures. High association with pubic rami fractures. *Clin Rheumatol.* Oct 2000;19(5):399-401. PMID 11055834
8. Leroux JL, Denat B, Thomas E, et al. Sacral insufficiency fractures presenting as acute low-back pain. Biomechanical aspects. *Spine (Phila Pa 1976).* Dec 1993;18(16):2502-2506. PMID 8303454
9. Newhouse KE, el-Khoury GY, Buckwalter JA. Occult sacral fractures in osteopenic patients. *J Bone Joint Surg Am.* Dec 1992;74(10):1472-1477. PMID 1364816
10. Blue Cross and Blue Shield Technology Evaluation Center (TEC). Percutaneous Vertebroplasty. TEC Assessments. 2000;Volume 15:Tab 21.
11. Blue Cross and Blue Shield Technology Evaluation Center (TEC). Percutaneous vertebroplasty for vertebral fractures caused by osteoporosis, malignancy, or hemangioma. TEC Assessments. 2004;Volume 19:Tab 13.
12. Blue Cross and Blue Shield Technology Evaluation Center (TEC). Percutaneous vertebroplasty for vertebral fractures caused by osteoporosis or malignancy. TEC Assessments. 2005;Volume 20:Tab 6.
13. Blue Cross and Blue Shield Technology Evaluation Center (TEC). Percutaneous vertebroplasty or kyphoplasty for vertebral fractures caused by osteoporosis or malignancy. TEC Assessments. 2008;Volume 23:Tab 5.
14. Blue Cross and Blue Shield Technology Evaluation Center (TEC). Percutaneous vertebroplasty or kyphoplasty for vertebral fractures caused by osteoporosis. TEC Assessments. 2009;Volume 24:Tab 7.
15. Blue Cross and Blue Shield Technology Evaluation Center (TEC). Percutaneous vertebroplasty for vertebral fractures caused by osteoporosis. TEC Assessments. 2010;Volume 25:Tab 9.

16. Buchbinder R, Golmohammadi K, Johnston RV, et al. Percutaneous vertebroplasty for osteoporotic vertebral compression fracture. *Cochrane Database Syst Rev.* Apr 30 2015(4):CD006349. PMID 25923524
17. Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. *N Engl J Med.* Aug 6 2009;361(6):557-568. PMID 19657121
18. Kallmes DF, Comstock BA, Heagerty PJ, et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures. *N Engl J Med.* Aug 6 2009;361(6):569-579. PMID 19657122
19. Staples MP, Kallmes DF, Comstock BA, et al. Effectiveness of vertebroplasty using individual patient data from two randomised placebo controlled trials: meta-analysis. *BMJ.* Jul 12 2011;343:d3952. PMID 21750078
20. Xie L, Zhao ZG, Zhang SJ, et al. Percutaneous vertebroplasty versus conservative treatment for osteoporotic vertebral compression fractures: An updated meta-analysis of prospective randomized controlled trials. *Int J Surg.* Nov 2017;47:25-32. PMID 28939236
21. Kroon F, Staples M, Ebeling PR, et al. Two-year results of a randomized placebo-controlled trial of vertebroplasty for acute osteoporotic vertebral fractures. *J Bone Miner Res.* Jun 2014;29(6):1346-1355. PMID 24967454
22. Ostelo RW, Deyo RA, Stratford P, et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. *Spine (Phila Pa 1976).* Jan 1 2008;33(1):90-94. PMID 18165753
23. Comstock BA, Sitlani CM, Jarvik JG, et al. Investigational vertebroplasty safety and efficacy trial (INVEST): patient-reported outcomes through 1 year. *Radiology.* Oct 2013;269(1):224-231. PMID 23696683
24. Chen D, An ZQ, Song S, et al. Percutaneous vertebroplasty compared with conservative treatment in patients with chronic painful osteoporotic spinal fractures. *J Clin Neurosci.* Mar 2014;21(3):473-477. PMID 24315046
25. Farrokhi MR, Alibai E, Maghami Z. Randomized controlled trial of percutaneous vertebroplasty versus optimal medical management for the relief of pain and disability in acute osteoporotic vertebral compression fractures. *J Neurosurg Spine.* May 2011;14(5):561-569. PMID 21375382
26. Edidin AA, Ong KL, Lau E, et al. Mortality risk for operated and nonoperated vertebral fracture patients in the Medicare population. *J Bone Miner Res.* Jul 2011;26(7):1617-1626. PMID 21308780
27. Edidin AA, Ong KL, Lau E, et al. Morbidity and mortality after vertebral fractures: comparison of vertebral augmentation and nonoperative management in the Medicare population. *Spine (Phila Pa 1976).* Aug 01 2015;40(15):1228-1241. PMID 26020845
28. Lin JH, Chien LN, Tsai WL, et al. Early vertebroplasty associated with a lower risk of mortality and respiratory failure in aged patients with painful vertebral compression fractures: a population-based cohort study in Taiwan. *Spine J.* Sep 2017;17(9):1310-1318. PMID 28483705
29. Clark W, Bird P, Gonski P, et al. Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet.* Oct 01 2016;388(10052):1408-1416. PMID 27544377
30. Klazen CA, Lohle PN, de Vries J, et al. Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. *Lancet.* Sep 25 2010;376(9746):1085-1092. PMID 20701962
31. Yi X, Lu H, Tian F, et al. Recompression in new levels after percutaneous vertebroplasty and kyphoplasty compared with conservative treatment. *Arch Orthop Trauma Surg.* Jan 2014;134(1):21-30. PMID 24287674
32. Leali PT, Solla F, Maestretti G, et al. Safety and efficacy of vertebroplasty in the treatment of osteoporotic vertebral compression fractures: a prospective multicenter international randomized controlled study. *Clin Cases Miner Bone Metab.* Sep-Dec 2016;13(3):234-236. PMID 28228788
33. Yang EZ, Xu JG, Huang GZ, et al. Percutaneous Vertebroplasty versus conservative treatment in aged patients with acute osteoporotic vertebral compression fractures: a prospective randomized controlled clinical study. *Spine (Phila Pa 1976).* Apr 2016;41(8):653-660. PMID 26630417
34. Frey ME, Depalma MJ, Cifu DX, et al. Percutaneous sacroplasty for osteoporotic sacral insufficiency fractures: a prospective, multicenter, observational pilot study. *Spine J.* Mar-Apr 2008;8(2):367-373. PMID 17981097

35. Kortman K, Ortiz O, Miller T, et al. Multicenter study to assess the efficacy and safety of sacroplasty in patients with osteoporotic sacral insufficiency fractures or pathologic sacral lesions. *J Neurointerv Surg*. Sep 1 2013;5(5):461-466. PMID 22684691
36. Frey ME, Warner C, Thomas SM, et al. Sacroplasty: a ten-year analysis of prospective patients treated with percutaneous sacroplasty: literature review and technical considerations. *Pain Physician*. Nov 2017;20(7):E1063-E1072. PMID 29149151
37. Dougherty RW, McDonald JS, Cho YW, et al. Percutaneous sacroplasty using CT guidance for pain palliation in sacral insufficiency fractures. *J Neurointerv Surg*. Jan 2014;6(1):57-60. PMID 23345629
38. Zaman FM, Frey M, Slipman CW. Sacral stress fractures. *Curr Sports Med Rep*. Feb 2006;5(1):37-43. PMID 16483515
39. Denis F, Davis S, Comfort T. Sacral fractures: an important problem. Retrospective analysis of 236 cases. *Clin Orthop Relat Res*. Feb 1988;227:67-81. PMID 3338224
40. Barr JD, Jensen ME, Hirsch JA, et al. Position statement on percutaneous vertebral augmentation: a consensus statement developed by the Society of Interventional Radiology (SIR), American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS), American College of Radiology (ACR), American Society of Neuroradiology (ASNR), American Society of Spine Radiology (ASSR), Canadian Interventional Radiology Association (CIRA), and the Society of NeuroInterventional Surgery (SNIS). *J Vasc Interv Radiol*. Feb 2014;25(2):171-181. PMID 24325929
41. Baerlocher MO, Saad WE, Dariushnia S, et al. Quality improvement guidelines for percutaneous vertebroplasty. *J Vasc Interv Radiol*. Feb 2014;25(2):165-170. PMID 24238815
42. McGuire RAJ. AAOS Now: Treating spinal compression fractures. 2010; <https://www.aaos.org/AAOSNow/2010/Oct/cover/cover1/?ssopc=1>. Accessed March 16, 2018.
43. National Institute for Health and Care Excellence (NICE). Percutaneous vertebroplasty [IPG12]. 2003; <https://www.nice.org.uk/guidance/ipg12>. Accessed March 16, 2018.
44. National Institute for Health and Care Excellence (NICE). Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures [TA279]. 2013; <https://www.nice.org.uk/guidance/ta279>. Accessed March 16, 2018.
45. National Institute for Health and Care Excellence (NICE). Metastatic spinal cord compression in adults: risk assessment, diagnosis and management [CG75]. 2008; <https://www.nice.org.uk/guidance/cg75/chapter/1-guidance>. Accessed March 16, 2018.

Billing Coding/Physician Documentation Information

- | | |
|--------------|--|
| 22510 | Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; cervicothoracic |
| 22511 | Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; lumbosacral |
| 22512 | Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; each additional cervicothoracic or lumbosacral vertebral body (List separately in addition to code for primary procedure) |
| 0200T | Percutaneous sacral augmentation (sacroplasty), unilateral injection(s), including the use of a balloon or mechanical device, when used, 1 or more needles |
| 0201T | Percutaneous sacral augmentation (sacroplasty), bilateral injections, including the use of a balloon or mechanical device, when used, 2 or more needles |

ICD-10 Codes

- C41.2** Malignant neoplasm of vertebral column
- C79.510-** Secondary malignant neoplasm of bone and bone marrow; code range
- C75.52**
- C90.00-** Multiple myeloma; code range
- C90.02**
- D18.09** Hemangioma of other sites
- D47.Z9** Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related issues
- M48.50-** Collapsed vertebra, not elsewhere classified; code range
- M48.58**
- M80.08** Age related osteoporosis with current pathological fracture, vertebra(e)
- M84.48** Pathological fracture, other site
- M84.58** Pathological fracture in neoplastic disease, vertebrae
- M84.68** Pathological fracture in other disease, other site

CPT 22520, 22521 and 22522 were deleted 1/1/2015.

HCPCS Codes S2360 and 2361 deleted 1/1/2016.

Additional Policy Key Words

N/A

Policy Implementation/Update Information

- 2/1/01 New policy. Added to Radiology section, considered medically necessary for certain indications.
- 2/1/02 No policy statement changes.
- 2/1/03 No policy statement changes. Added CPT codes.
- 6/1/04 Policy statement revised to include discussion of percutaneous kyphoplasty as investigational. Policy statement revised to indicate percutaneous vertebroplasty as investigational except when pain is severe and debilitating, and cannot be relieved by correct medical therapy, other causes of pain, such as herniated intervertebral disk have been ruled out, and the affected vertebra has not been extensively destroyed and is at least one-third of its original height.
- 2/1/05 No policy statement changes.
- 2/1/06 Added to Surgery section. Removed percutaneous kyphoplasty from this policy and is now discussed under a separate policy.
- 2/1/07 No policy statement changes. Coding Updated.
- 2/1/08 No policy statement changes.
- 10/7/08 Policy statement revised; medically necessary if not responding to conservative treatment.
- 11/1/09 No policy statement changes.
- 11/1/10 Policy statement revised to indicate use in acute vertebral fractures as investigational.
- 11/1/11 Policy revised to include percutaneous sacroplasty (previously addressed in a separate policy); remains investigational. No changes to the policy statements on percutaneous vertebroplasty.

- 11/1/12 No policy statement changes.
 - 11/1/13 No policy statement changes.
 - 11/1/14 No policy statement changes.
 - 11/1/15 Updated CPT codes. No policy statement changes.
 - 11/1/16 "Spinal lesions" in 4th policy statement changed to "sacral lesions" to clarify the intent.
 - 7/1/17 Added; vertebroplasty may be medically necessary in vertebral fractures of less than 6 weeks duration that prevent ambulation.

 - 11/1/17 No policy statement changes.
 - 11/1/18 No policy statement changes.
-

State and Federal mandates and health plan contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The medical policies contained herein are for informational purposes. The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents Blue KC and are solely responsible for diagnosis, treatment and medical advice. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, photocopying, or otherwise, without permission from Blue KC.